Page 3 - Torrent Pharmaceuticals

Top Headlines: Reliance to acquire METRO AG's India biz, Covid-19 alert

Business Standard brings you the top headlines at this hour

After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Number of deals down 42% in October but matches pre-pandemic level: Report

According to GT Bharat's monthly Dealtracker, the biggest deal in October was Torrent Pharma's $250 million acquisition of Curatio Healthcare

Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%

The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it

F&O expiry: Nifty holds 16,800, Sensex dips 188 pts day ahead of RBI policy

CLOSING BELL: ITC, Dr Reddy's Labs, Tata Steel, Sun Pharma, M&M, NTPC, and Nestle India were the top large-cap winners, while Asian Paints, Tech M, Wipro, TCS, Titan, Kotak Bank sank

LIC, Nykaa, Tata Motors: Are these buzzing stocks bottoming out?

Sun Pharmaceutical seems set to register a new 52-week high; while Tata Motors and Torrent Pharmaceuticals are yet to take-off their respective obstacles, charts show.

Expensive deal valuations to hit Torrent Pharma's near-term earnings

Sales trajectory in domestic formulations and resolution of regulatory issues are other triggers

Stocks to Watch: Torrent Pharma, ONGC, Dr Reddy's, BHEL, BPCL, Birla Corp

Stocks to Watch: Dr Reddy's has received US FDA nod for marketing Timolol Maleate, which is used to treat Glaucoma

Torrent Pharma acquires cosmetic derma player Curatio for Rs 2,000 cr

First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August

Torrent Pharma to acquire Sequoia-backed Curatio Health for Rs 2,000 cr

Torrent Pharmaceuticals on Tuesday said it will acquire Curatio Healthcare for Rs 2,000 crore to strengthen its presence in the dermatology segment. The company has entered into definitive agreements to acquire 100 per cent of Curatio Healthcare for Rs 2,000 crore, Torrent Pharmaceuticals said in a regulatory filing. "The consideration includes Rs 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an enterprise value of Rs 1,885 crore," it added. The acquisition offers Torrent the opportunity to enhance its presence in dermatology with a differentiated portfolio and is a strong strategic fit, Torrent Pharmaceuticals Director Aman Mehta said. "Curatio has built a commendable set of high market share brands in cosmetic and pediatric dermatology that we look forward to adding to our product offerings," he added. Chennai-headquartered Curatio has a portfolio of over 50 brands, including Tedibar, Atogla, Spoo, B4 Nappi and Permite, in th

Torrent group to make Rs 2,900-cr bid for Reliance Nippon Life Insurance

Reliance Capital is undergoing a bankruptcy process and the administrator had sought offers for the entire company and for its various business clusters

Rise of cosmetic dermatology space gets big pharma looking for buyouts

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Torrent Pharma expected to enter diagnostics space in next 2-3 months

A company called Torrent Diagnostics Private Ltd was incorporated in February this year and has a Torrent Pharmaceuticals executive director as one of its directors

Strong domestic outlook remains key growth driver for Torrent Pharma

Cost savings could drive Torrent Pharma's margins higher in the near term

Torrent Pharma acquires four therapy segment brands from Dr Reddy's

Styptovit-E, a gynaecology product, has an estimated market size of roughly Rs 500 crore, according to data from AIOCD, a pharmaceutical market research company

Torrent Pharma rallies 9% on 1:1 bonus issue plan, dividend of Rs 23/share

In Q4, the company posted net loss of Rs 118 crore against profit of Rs 324 crore in the year ago quarter

Torrent Pharma posts Rs 118 cr Q4 loss vs Rs 324 cr profit a year ago

The red line comes amid headwinds in EU operatopns and discontinuation of liquids business in the US; revenue, however, grows by 10%

19 Indian companies sign licensing pact for Pfizer's oral Covid drug

Torrent Pharma and Cadila Pharma sign licensing agreement with MPP to make and market the drug

Cadila, Torrent get licence to make generic version of Pfizer's Covid pill

Pharma firms enter into licensing agreement with Medicine Patent Pool to use nirmatrelvir compound for making PAXLOVID